A Blood Protein Signature Stratifies Clinical Response to csDMARD Therapy in Pediatric Uveitis.

ABSTRACT:

Purpose

To identify a serum biomarker signature that can help predict response to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy in pediatric noninfectious uveitis.

Methods

In this case-control cohort study, we performed a 368-plex proteomic analysis of serum samples of 72 treatment-free patients with active uveitis (new onset or relapse) and 15 healthy controls. Among these, 37 patients were sampled at diagnosis before commencing csDMARD therapy. After 6 months, csDMARD response was evaluated and cases were categorized as "responder" or "nonresponder." Patients were considered "nonresponders" if remission was not achieved under csDMARD therapy. Serum protein profiles were used to train random forest models to predict csDMARD failure and compar

SUBMITTER: Wennink RAW 

PROVIDER: S-EPMC8819312 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature